Molecular Formula | C6H4ClN3 |
Molar Mass | 153.57 |
Density | 1.61±0.1 g/cm3(Predicted) |
Melting Point | 188-194 °C |
Boling Point | 289.2±50.0 °C(Predicted) |
Solubility | Soluble in DMSO, ethyl acetate and methanol. |
Vapor Presure | 0Pa at 25℃ |
Appearance | Bright brown powder |
Color | White to tan |
pKa | 11.42±0.20(Predicted) |
Storage Condition | Keep in dark place,Inert atmosphere,2-8°C |
MDL | MFCD01686865 |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R25 - Toxic if swallowed R20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S37 - Wear suitable gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36 - Wear suitable protective clothing. |
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | UY9360000 |
TSCA | No |
HS Code | 29335990 |
Hazard Class | IRRITANT |
Packing Group | Ⅲ |
LogP | 0.858 at 30℃ |
Overview | 4-Clopyrimidine is an important pharmaceutical intermediate, which is used as an intermediate for the treatment of moderate to severe rheumatoid arthritis adult patients with insufficient or intolerant methotrexate. 4-Clopyrroxidine is also an important raw material for the development of many antibacterial, anti-tumor, anti-vertebral and other drugs. |
Application | 4-Clopyrroxidine white to white powder for the treatment of moderate to severe rheumatoid arthritis with insufficient or intolerance of methotrexate Intermediate of the drug substance tofaitinib in adult patients; tofaitinib intermediate. |
use | intermediate of tofacitinib citrate (540737-29-9,Tofacitinib citrate) |